Drug Discovery Technologies

Global Drug Discovery Technologies Market to Reach US$124.2 Billion by 2030

The global market for Drug Discovery Technologies estimated at US$75.4 Billion in the year 2024, is expected to reach US$124.2 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end of the analysis period. Growth in the Biologics segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.2 Billion While China is Forecast to Grow at 10.6% CAGR

The Drug Discovery Technologies market in the U.S. is estimated at US$20.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$19.0 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Drug Discovery Technologies Market - Key Trends & Drivers Summarized

What Are Drug Discovery Technologies and How Do They Propel Pharmaceutical Innovation?
Drug discovery technologies comprise a broad range of methods and tools used in the identification and development of new therapeutic drugs. These technologies are critical in the pharmaceutical industry as they streamline the process of discovering and optimizing new compounds that may become the next generation of medications. Key technologies include high-throughput screening (HTS), genomics, proteomics, bioinformatics, and artificial intelligence (AI). HTS allows researchers to quickly conduct millions of chemical, genetic, or pharmacological tests, dramatically speeding up the discovery of active compounds that could lead to viable drugs. Genomics and proteomics provide insights into the genetic and protein expressions related to diseases, offering new targets for drug therapy.

How Is Artificial Intelligence Transforming Drug Discovery?
Artificial intelligence (AI) is revolutionizing the drug discovery process by offering unprecedented data processing capabilities and predictive power. AI algorithms can analyze vast datasets from drug trials, patient records, and genetic information to identify potential drug candidates with higher precision and at a fraction of the time and cost compared to traditional methods. Machine learning models are particularly adept at recognizing complex patterns in data, predicting how different chemicals will interact with the human body, and suggesting modifications to chemical structures to enhance efficacy and reduce side effects. As AI technology continues to evolve, its integration into drug discovery processes is becoming increasingly indispensable, enabling more targeted and effective therapies.

What Challenges and Opportunities Exist in the Adoption of New Drug Discovery Technologies?
While the integration of advanced technologies in drug discovery presents significant opportunities for the development of effective treatments, it also introduces challenges. The high cost of new technologies, such as robotics and AI platforms, can be a barrier for smaller pharmaceutical companies and research institutions. Additionally, managing and analyzing the enormous volumes of data generated by these technologies require substantial investments in data management infrastructure and skilled personnel. Despite these challenges, the potential to drastically reduce the time and cost associated with drug development is a compelling incentive for continued investment. Emerging markets are also recognizing the value of these technologies, leading to increased adoption worldwide.

What Drives the Growth in the Drug Discovery Technologies Market?
The growth in the drug discovery technologies market is driven by several factors, including the urgent need for new medical treatments, advancements in technology, and increased funding and investment in R&D by pharmaceutical companies and governments. The rising prevalence of chronic and infectious diseases worldwide demands faster and more efficient development of effective drugs. Technological advancements that offer enhanced capabilities and efficiencies in discovering new drugs are critical in meeting these health challenges. Additionally, the pharmaceutical industry`s focus on precision medicine tailored to genetic profiles is pushing the boundaries of traditional drug discovery, further fueling the demand for advanced technologies.

SCOPE OF STUDY:

The report analyzes the Drug Discovery Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Small Molecule Drugs, Biologics); Technology (High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology, Other Technologies); End-Use (Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Other End-Uses)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 129 Featured) -

• Agilent Technologies, Inc.
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• Alnylam Pharmaceuticals, Inc.
• Antares Pharma, Inc.
• Ambrx, Inc.
• ActivX Biosciences, Inc.
• Alembic Pharmaceuticals Limited
• BioVision, Inc.
• Acadia Pharmaceuticals, Inc.
• Beactica Therapeutics AB
• Atomwise, Inc.
• BeiGene LTD.
• ATXA Therapeutics
• Bayer Pharmaceuticals

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.